Reply: Will FTLD-tau work for all when FTDP-17 retires?

Shelley L Forrest¹, Jillian J Kril¹, Glenda M Halliday^{2

3}

Affiliations

¹ Charles Perkins Centre and Discipline of Pathology, Faculty of Medicine and Health, University of Sydney, Australia.
² Brain and Mind Centre and Central Clinical School, Faculty of Medicine and Health, University of Sydney, Australia.
³ Neuroscience Research Australia and School of Medical Sciences, University of New South Wales, Australia.

Comment

Shelley L Forrest et al. Brain. 2018.

. 2018 Aug 1;141(8):e63.

doi: 10.1093/brain/awy179.

Shelley L Forrest¹, Jillian J Kril¹, Glenda M Halliday^{2

3}

¹ Charles Perkins Centre and Discipline of Pathology, Faculty of Medicine and Health, University of Sydney, Australia.
² Brain and Mind Centre and Central Clinical School, Faculty of Medicine and Health, University of Sydney, Australia.
³ Neuroscience Research Australia and School of Medical Sciences, University of New South Wales, Australia.

No abstract available

Comment on

Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies.
Forrest SL, Kril JJ, Stevens CH, Kwok JB, Hallupp M, Kim WS, Huang Y, McGinley CV, Werka H, Kiernan MC, Götz J, Spillantini MG, Hodges JR, Ittner LM, Halliday GM. Forrest SL, et al. Brain. 2018 Feb 1;141(2):521-534. doi: 10.1093/brain/awx328. Brain. 2018. PMID: 29253099 Free PMC article.
Will FTLD-tau work for all when FTDP-17 retires?
Ygland E, Landqvist Waldö M, Englund E, Puschmann A, Nilsson C. Ygland E, et al. Brain. 2018 Aug 1;141(8):e62. doi: 10.1093/brain/awy178. Brain. 2018. PMID: 29947741 No abstract available.